The FDA gives marketing approval for a test that screens for Duchenne muscular dystrophy in newborns; acetaminophen is facing a possible statewide ban in California; the Supreme Court will not rush its decision on the Affordable Care Act.
The FDA has given marketing approval for the GSP Neonatal Creatine Kinase-MM kit, which tests for Duchenne muscular dystrophy (DMD) in newborns, making it the first such approval for the rare muscle disorder, according to JAMA. Laboratories now have the choice to add this test to their newborn screening panels, as it is not yet required by HHS’ Recommended Uniform Screening Panel for newborn screenings. Results can detect potential muscle injury, but they must be confirmed via muscle biopsy or genetic testing.
Acetaminophen, an integral ingredient in more than 600 prescription and OTC medications, is facing a ban in California, says MSN. Although it is often used to reduce fevers and pain, acetaminophen also is closely connected to phenacetin, which was banned in 1983 because it was shown to cause cancer. Proposition 65 mandates that California has to warn its citizens of cancerous chemicals. Those opposed to reclassifying acetaminophen under this law caution against the weak cancer link, while supporters emphasize product safety. The public comment period closes on January 27.
Democrats were disheartened yesterday when the Supreme Court refused to hand down a final decision on the Affordable Care Act (ACA) before this year’s presidential election, details Politico. The justices claim there is no “emergency,” while Democrats worry about possible harm to those who currently have coverage under the law. Previously, a federal judge in Texas declared the ACA unconstitutional. Republicans, meanwhile, cannot agree on an ACA replacement. Last summer, CMS Administrator Seema Verma’s plan was struck down. The new Supreme Court term begins in October.
What We’re Reading: Abortion Privacy Rules; Alzheimer Drug Hurdles; Nursing Home Staffing Overhaul
April 23rd 2024New health privacy rules aim to protect patients and providers in an evolving abortion landscape; some physicians express concerns about efficacy, risks, and entrenched beliefs in treating Alzheimer disease; CMS addresses longstanding staffing deficits in nursing homes.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen